title: Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
authors.forename: O
authors.initials: O
authors.lastname: Flossmann
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
authors.forename: D R W
authors.initials: DR
authors.lastname: Jayne
authors.forename: R A
authors.initials: RA
authors.lastname: Luqmani
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008212:Lymphocyte Depletion; D012074:Remission Induction; D000069283:Rituximab; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab